tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Vaxxinity Inc (VAXX), Amgen (AMGN) and LivaNova (LIVN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vaxxinity Inc (VAXXResearch Report), Amgen (AMGNResearch Report) and LivaNova (LIVNResearch Report) with bullish sentiments.

Vaxxinity Inc (VAXX)

In a report issued on December 2, Roger Song from Jefferies maintained a Buy rating on Vaxxinity Inc, with a price target of $15.00. The company’s shares closed last Friday at $2.04, close to its 52-week low of $1.26.

According to TipRanks.com, Song has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -27.2% and a 24.6% success rate. Song covers the Healthcare sector, focusing on stocks such as Kinnate Biopharma, IGM Biosciences, and Replimune Group.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vaxxinity Inc with a $15.00 average price target.

See the top stocks recommended by analysts >>

Amgen (AMGN)

In a report released yesterday, Michael Yee from Jefferies maintained a Buy rating on Amgen, with a price target of $325.00. The company’s shares closed last Friday at $285.51, close to its 52-week high of $296.67.

According to TipRanks.com, Yee is a 2-star analyst with an average return of 0.0% and a 46.2% success rate. Yee covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Olema Pharmaceuticals, and Immunocore Holdings.

The word on The Street in general, suggests a Hold analyst consensus rating for Amgen with a $259.57 average price target.

LivaNova (LIVN)

In a report released yesterday, Matthew Taylor from Jefferies reiterated a Buy rating on LivaNova, with a price target of $80.00. The company’s shares closed last Friday at $55.69.

According to TipRanks.com, Taylor is a 5-star analyst with an average return of 12.5% and a 64.5% success rate. Taylor covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Establishment Labs Holdings, and Zimmer Biomet Holdings.

Currently, the analyst consensus on LivaNova is a Strong Buy with an average price target of $74.80, which is a 35.1% upside from current levels. In a report issued on November 23, Goldman Sachs also maintained a Buy rating on the stock with a $63.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on VAXX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles